Risk of cutaneous adverse events in cancer patients treated with phosphatidylinositol‐3‐kinase inhibitors: A systematic review and meta‐analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Risk of cutaneous adverse events in cancer patients treated with phosphatidylinositol‐3‐kinase inhibitors: A systematic review and meta‐analysis of randomized controlled trials

Published:2022-08-19 Issue:3 Volume:12 Page:2227-2237
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Wang Yushu¹²^ORCID,Ma Zhuo¹^ORCID,An Zhuoling¹,Zhang Yi¹²^ORCID,Feng Xin²,Yu Xiaojia¹

Affiliation:

1. Department of Pharmacy Beijing Chao‐Yang Hospital, Capital Medical University Beijing China

2. Department of Pharmacy Beijing Obstetrics and Gynecology Hospital, Capital Medical University. Beijing Maternal and Child Health Care Hospital Beijing China

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5153

Reference69 articles.

1. The present and future of PI3K inhibitors for cancer therapy

2. PI3K inhibitors are finally coming of age

3. CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

4. PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models

5. Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of PI3K inhibitor-related cutaneous AEs;Reactions Weekly;2022-08-27